The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance o...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, James D, Darimont, Beatrice, Zhou, Wei, Arrazate, Alfonso, Young, Amy, Ingalla, Ellen, Walter, Kimberly, Blake, Robert A, Nonomiya, Jim, Guan, Zhengyu, Kategaya, Lorna, Govek, Steven P, Lai, Andiliy G, Kahraman, Mehmet, Brigham, Dan, Sensintaffar, John, Lu, Nhin, Shao, Gang, Qian, Jing, Grillot, Kate, Moon, Michael, Prudente, Rene, Bischoff, Eric, Lee, Kyoung-Jin, Bonnefous, Celine, Douglas, Karensa L, Julien, Jackaline D, Nagasawa, Johnny Y, Aparicio, Anna, Kaufman, Josh, Haley, Benjamin, Giltnane, Jennifer M, Wertz, Ingrid E, Lackner, Mark R, Nannini, Michelle A, Sampath, Deepak, Schwarz, Luis, Manning, Henry Charles, Tantawy, Mohammed Noor, Arteaga, Carlos L, Heyman, Richard A, Rix, Peter J, Friedman, Lori, Smith, Nicholas D, Metcalfe, Ciara, Hager, Jeffrey H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2016
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961458/
https://www.ncbi.nlm.nih.gov/pubmed/27410477
http://dx.doi.org/10.7554/eLife.15828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961458/
https://www.ncbi.nlm.nih.gov/pubmed/27410477
http://dx.doi.org/10.7554/eLife.15828

Ejemplares similares